List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 where FÉNOFIBRATE BIOGARAN 300 mg, gélule FENOFIBRATE TEVA SANTE 160 mg, comprimé pelliculé not available BIOGARAN FR not available NL31090 TEVA SANTÉ FR Lipofen 100 mg cápsula not available LABORATÓRIOS VITÓRIA, SA Lipofen 100 mg cápsula not available LABORATÓRIOS VITÓRIA, SA Elipsia 145 mg Filmtablette not available ABBOTT LABORATORIES Fenofibrat Abbott 160mg Filmtabletten not available ABBOTT LABORATORIES Lipanthyl 200 mg, kapsel, hård IE/H/0120/ MYLAN MEDICAL SAS SE Lipantil Micro 200 mg capsule, hard IE/H/0120/002 PA 2010/15/2 MYLAN IRE HEALTHCARE IE Apteor 160 mg Filmtablette /H/0236/ MYLAN HEALTHCARE /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT EMA/243033/2018 Page 2/13

3 where /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT /H/0236/ BGP PRODUCTS S.R.L. IT Lipanthyl S 215 mg, potahovaná tableta Lipanthyl Supra 215 mg, 215 mg, tabletki powlekane LIPANTHYL SUPRA 215 mg filmom obalené tablety Lipantil Supra 215 mg, filmcoated tablet IE/H/0157/001 31/288/05-C MYLAN IRE HEALTHCARE IE/H/0157/ BGP PRODUCTS POLAND SP. Z.O.O. IE/H/0157/001 31/0390/05-S MYLAN IRE HEALTHCARE IE/H/0157/001 PA 2010/15/4 MYLAN IRE HEALTHCARE CZ PL SK IE Secalip 250 mg cápsulas duras de liberación prolongada not available LACER S.A. ES Secalip 200 mg cápsulas duras not available LACER S.A. ES Secalip supra 160 mg comprimidos recubiertos con película /H/0235/ LACER S.A. ES EMA/243033/2018 Page 3/13

4 where Secalip 145 mg comprimidos recubiertos con película /H/0497/ LACER S.A. ES Lipcor 200 mg-kapseln not available BGP PRODUCTS GES. M. B. H. AT Secalip 250 mg cápsulas duras de liberación prolongada not available LACER S.A. ES Secalip 200 mg cápsulas duras not available LACER S.A. ES CATALIP 200 mg cápsulas not available LABORATÓRIO MEDINFAR CATALIP 200 mg cápsulas not available LABORATÓRIO MEDINFAR CATALIP 267 MICRONIZADO 267 mg cápsulas Catalip 267 Micronizado 267 mg cápsulas Lipanthyl 200 Micronised, 200 mg Hartkapseln not available LABORATÓRIO MEDINFAR not available LABORATÓRIO MEDINFAR not available BE MYLAN EPD SPRL BE Lipanthyl 267 Micronised, 267 mg Hartkapseln LIPANTHYL 267 Micronised, 267 mg, capsules, hard Lipanthyl 67 Micronised, 67 mg Hartkapseln LIPANTHYL 267 Micronised gélules not available BE MYLAN EPD SPRL BE not available BE MYLAN EPD SPRL BE not available BE MYLAN EPD SPRL BE not available BE MYLAN EPD SPRL BE EMA/243033/2018 Page 4/13

5 where LIPANTHYL 267 Micronised gélules LIPANTHYL 200 Micronised gélules LIPANTHYL 67 Micronised, 67 mg gélules not available MYLAN EPD SPRL LU not available BE MYLAN EPD SPRL BE not available BE MYLAN EPD SPRL BE LIPANTHYL-200 MICRONISED not available MYLAN EPD SPRL LU LIPANTHYL 67 Micronised, 67 mg gélules LIPANTHYL 200 Micronised, capsules, hard LIPANTHYL 67 Micronised, capsules, hard Липантил Супра 160 mg филмирани таблетки Липантил 200M 200 mg капсули, твърди not available MYLAN EPD SPRL LU not available BE MYLAN EPD SPRL BE not available BE MYLAN EPD SPRL BE not available MYLAN MEDICAL SAS BG not available MYLAN MEDICAL SAS BG Lipidil NT 145 mg, filmcoated tablet LIPANTHYL SUPRA 160 mg Potahovaná tableta LIPANTHYL 267 M tvrdá tobolka not available VARNAVAS HADJIPANAYIS LTD. (LATSIA) not available 31/463/00-C MYLAN IRE HEALTHCARE not available 31/105/00-C MYLAN IRE HEALTHCARE CY CZ CZ Lipidil 200 mg Hartkapseln not available MYLAN HEALTHCARE EMA/243033/2018 Page 5/13

6 where Lipanthyl, 200 mg kõvakapslid not available BGP PRODUCTS SIA EE LIPANTHYL 200 micronisé, gélule LIPANTHYL 200 micronisé, gélule LIPANTHYL 200 micronisé, gélule not available MYLAN MEDICAL SAS FR not available MYLAN MEDICAL SAS FR not available MYLAN MEDICAL SAS FR LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR LIPIDIL 145 mg filmom obložene tablete TRICOR 145 mg filmom obložene tablete LIPIDIL 160 mg filmom obložene tablete TRICOR 160 mg filmom obložene tablete TRICOR 215 mg filmom obložene tablete not available UP/I /12-02/101 MYLAN HRVATSKA D.O.O. HR not available UP/I /12-02/102 MYLAN HRVATSKA D.O.O. HR not available UP/I /12-02/99 MYLAN HRVATSKA D.O.O. HR not available UP/I /12-02/100 MYLAN HRVATSKA D.O.O. HR not available UP/I /12-02/104 MYLAN HRVATSKA D.O.O. HR Lipidil Supra 160 mg filmtabletta not available OGYI-T-7695/01 MYLAN PRODUCTS HU Lipidil 267 mg kemény kapszula not available OGYI-T-8697/01 MYLAN EPD KFT. HU FULCRO 200 mg capsule rigide not available BGP PRODUCTS S.R.L. IT LIPANTHYL 200 mg kietosios kapsulės not available LT/1/96/2568/001 MYLAN MEDICAL SAS LT EMA/243033/2018 Page 6/13

7 where LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR LIPANTHYL 67 Micronisé, gélule not available MYLAN MEDICAL SAS FR Lipanthyl 200 mg cietās kapsulas not available BGP PRODUCTS SIA LV Lipanthyl Supra 160, 160 mg, tabletki powlekane Lipanthyl 200M, 200 mg, kapsułki Lipanthyl 267M, 267 mg, kapsułki not available 9039 BGP PRODUCTS POLAND SP. Z.O.O. not available R/2587 BGP PRODUCTS POLAND SP. Z.O.O. not available 4928 BGP PRODUCTS POLAND SP. Z.O.O. PL PL PL LIPANTIL NANO 145 mg comprimate filmate Lipanthyl Supra 160 mg comprimate cu eliberare modificată Lipanthyl Supra 160 mg comprimate cu eliberare modificată LIPANTHYL SUPRA 160 mg filmom obalené tablety not available 9126/2016/01 MYLAN MEDICAL SAS RO not available 1075/2008/02 MYLAN MEDICAL SAS RO not available 1075/2008/01 MYLAN MEDICAL SAS RO not available 31/0394/00-S MYLAN IRE HEALTHCARE SK EMA/243033/2018 Page 7/13

8 where Lipantil Micro 200 mg, capsules Lipantil Micro 267 mg, capsules Lipantil Micro 67 mg, capsules FENOFIBRATE EG 160 mg, comprimé pelliculé not available PL 46302/0042 MYLAN PRODUCTS not available PL 46302/0043 MYLAN PRODUCTS not available PL 46302/0044 MYLAN PRODUCTS not available NL31362 EG LABO LABORATOIRES EUROGENERICS UK UK UK FR LIPSIN 200 mg capsule rigide not available I.B.N. SAVIO S.R.L. IT Lipofene 100 mg capsule not available TEOFARMA S.R.L. IT FENOFIBRATE TEVA 300 mg, gélule FENOFIBRATE TEVA 100 mg, gélule not available NL21839 TEVA SANTÉ FR not available NL21838 TEVA SANTÉ FR Lipantil Micro 67 mg capsule, hard IE/H/0120/001 PA 2010/15/1 MYLAN IRE HEALTHCARE IE Secalip 145 mg comprimidos recubiertos con película /H/0497/ LACER S.A. ES Lipanthyl Nanopartikel 145 mg - Filmtabletten /H/0497/ BGP PRODUCTS GES. M. B. H. AT Lipanthylnano 145 mg Filmtabletten Lipanthylnano 145 mg comprimés pelliculés Lipanthylnano 145 mg comprimés pelliculés /H/0497/001 BE MYLAN EPD SPRL BE /H/0497/001 BE MYLAN EPD SPRL BE /H/0497/ MYLAN EPD SPRL LU EMA/243033/2018 Page 8/13

9 where Lipanthylnano 145 mg filmomhulde tabletten /H/0497/001 BE MYLAN EPD SPRL BE Lipanthyl NT 145 mg, potahované tablety /H/0497/001 31/214/05-C MYLAN IRE HEALTHCARE CZ Lipanthyl Penta 145 mg, kalvopäällysteinen tabletti LIPANTHYL 145 mg, comprimé pelliculé LIPANTHYL 145 mg, comprimé pelliculé LIPANTHYL 145 mg, comprimé pelliculé /H/0497/ MYLAN MEDICAL SAS FI /H/0497/ MYLAN MEDICAL SAS FR /H/0497/ MYLAN MEDICAL SAS FR /H/0497/ MYLAN MEDICAL SAS FR LIPIDIL NT 145mg επικαλυμμένο με λεπτό υμένιο δισκίο /H/0497/ / BGP PRODUCTS LTD (GREECE) Lipidil 145 mg filmtabletta /H/0497/001 OGYI-T-8967/02 MYLAN EPD KFT. HU GR /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT EMA/243033/2018 Page 9/13

10 where /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT /H/0497/ /M BGP PRODUCTS S.R.L. IT Lipanthyl NT 145, 145 mg, tabletki powlekane LIPANTHYL NT 145 mg filmom obalené tablety LIPIDIL 145 ONE 145 mg Filmtabletten Lipantil Supra 145 mg filmcoated tablet /H/0497/ BGP PRODUCTS POLAND SP. Z.O.O. /H/0497/001 31/0396/05-S MYLAN IRE HEALTHCARE /H/0497/ MYLAN HEALTHCARE /H/0497/001 PA 2010/15/3 MYLAN IRE HEALTHCARE PL SK IE Lipanthyl Penta 145 mg, filmdragerad tablett /H/0497/ MYLAN MEDICAL SAS FI /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT EMA/243033/2018 Page 10/13

11 where /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT /H/0500/ /M BGP PRODUCTS S.R.L. IT Liperial 145 mg Filmtablette /H/0500/ MYLAN HEALTHCARE Secalip supra 160 mg comprimidos recubiertos con película LIPANTHYL 160 mg, comprimé pelliculé LIPANTHYL 160 mg, comprimé pelliculé LIPANTHYL 160 mg, comprimé pelliculé /H/0235/ LACER S.A. ES /H/0235/ MYLAN MEDICAL SAS FR /H/0235/ MYLAN MEDICAL SAS FR /H/0235/ MYLAN MEDICAL SAS FR EMA/243033/2018 Page 11/13

12 where Supralip 160 mg, film-coated tablet Lipidil-Ter 160 mg Filmtablette /H/0235/001 PL 46302/0024 MYLAN PRODUCTS /H/0235/ MYLAN HEALTHCARE UK CATALIP 200 mg cápsulas not available LABORATÓRIO MEDINFAR CATALIP 200 mg cápsulas not available LABORATÓRIO MEDINFAR CATALIP 267 MICRONIZADO 267 mg cápsulas Catalip 267 Micronizado 267 mg cápsulas not available LABORATÓRIO MEDINFAR not available LABORATÓRIO MEDINFAR Xafenor 145 mg Filmtablette /H/0498/ MYLAN HEALTHCARE Supralip 145 mg comprimidos revestidos por película Supralip 145 mg comprimidos revestidos por película Supralip 145 mg comprimidos revestidos por película /H/0498/ BGP PRODUCTS UNIPESSOAL, LDA. /H/0498/ BGP PRODUCTS UNIPESSOAL, LDA. /H/0498/ BGP PRODUCTS UNIPESSOAL, LDA. Fenogal Lidose 200 mg gélules not available BE LABORATOIRES SMB S.A. BE Fenogal Lidose 200 mg capsules, hard Fenogal Lidose 200 mg Hartkapseln not available BE LABORATOIRES SMB S.A. BE not available BE LABORATOIRES SMB S.A. BE EMA/243033/2018 Page 12/13

13 where Fenogal Lidose 200 mg gélules not available LABORATOIRES SMB S.A. LU Fenogal Lidose 200 mg Hartkapseln FENOFIBRATE BIOGARAN 100 mg, gélule FENOFIBRATE BIOGARAN 100 mg, gélule FENOFIBRATE BIOGARAN 100 mg, gélule not available LABORATOIRES SMB S.A. LU not available BIOGARAN FR not available BIOGARAN FR not available BIOGARAN FR EMA/243033/2018 Page 13/13

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Aurobindo 5 mg film-coated tablets Simvastatin Aurobindo 10 mg film-coated tablets Simvastatin Aurobindo 20 mg film-coated tablets Simvastatin Aurobindo

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT BIJSLUITER: INFORMATIE VOOR DE PATIËNT Sitagliptine Teva 25 mg, filmomhulde tabletten Sitagliptine Teva 50 mg, filmomhulde tabletten Sitagliptine Teva 100 mg, filmomhulde tabletten Sitagliptin Read all

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Package leaflet: Information for the user Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Read all of this leaflet carefully before you start taking this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Bluefish 10 mg film-coated tablets Simvastatin Bluefish 20 mg film-coated tablets Simvastatin Bluefish 40 mg film-coated tablets Simvastatin Bluefish

More information

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Please note that this draft Annex I will be updated to amend information on concerned products/mahs 22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Atorvastatin 10 mg Film-coated Tablets Atorvastatin 20 mg Film-coated Tablets Atorvastatin 40 mg Film-coated Tablets Atorvastatin 80 mg Film-coated Tablets

More information

Fenofibrate containing medicinal products with Marketing Authorisation in the European Union

Fenofibrate containing medicinal products with Marketing Authorisation in the European Union Annex I List of the names, pharmaceutical s, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states 1 Fenofibrate containing medicinal products

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT PACKAGE LEAFLET 1 BIJSLUITER: INFORMATIE VOOR DE PATIËNT Cinacalcet 30 mg Teva, filmomhulde tabletten Cinacalcet 60 mg Teva, filmomhulde tabletten Cinacalcet 90 mg Teva, filmomhulde tabletten Cinacalcet

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Etoricoxib

PACKAGE LEAFLET: INFORMATION FOR THE USER. Etoricoxib PACKAGE LEAFLET: INFORMATION FOR THE USER ARCOXIA 30 mg film-coated tablets ARCOXIA 60 mg film-coated tablets ARCOXIA 90 mg film-coated tablets ARCOXIA 120 mg film-coated tablets Etoricoxib Read all of

More information

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel Package leaflet: Information for the user Clopidogrel 75 mg film-coated tablets Clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

MONTELAIR 10 mg film-coated tablets

MONTELAIR 10 mg film-coated tablets Package leaflet: Information for the user MONTELAIR 10 mg film-coated tablets For adolescents and adults from 15 years Montelukast Read all of this leaflet carefully before you start taking this medicine

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium

More information

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin Read all of this leaflet

More information

European Medicines Agency decision

European Medicines Agency decision EMA/398442/2016 European Medicines Agency decision P/0191/2016 of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)

More information

Package leaflet: information for the user

Package leaflet: information for the user Package leaflet: information for the user Rosuvastatin 5 mg film-coated tablets Rosuvastatin 10 mg film-coated tablets Rosuvastatin 20 mg film-coated tablets Rosuvastatin 40 mg film-coated tablets rosuvastatin

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Tevaquel 25 mg Film-coated Tablets Tevaquel 100 mg Film-coated Tablets Tevaquel 150 mg Film-coated Tablets Tevaquel 200 mg Film-coated Tablets Tevaquel 300

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib

PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib Read all of this leaflet carefully before you start taking this medicine. Keep this

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

Package leaflet: Information for the patient. Lercanidipine Mylan 10mg film-coated tablets lercanidipine hydrochloride

Package leaflet: Information for the patient. Lercanidipine Mylan 10mg film-coated tablets lercanidipine hydrochloride Package leaflet: Information for the patient Lercanidipine Mylan 10mg film-coated tablets lercanidipine hydrochloride Read all of this leaflet carefully before you start taking this medicine because it

More information

European Medicines Agency decision

European Medicines Agency decision EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for

More information

Package leaflet: Information for the user. Kalcipos-D forte 500 mg/800 IU film-coated tablets. Calcium/cholecalciferol (Vitamin D3)

Package leaflet: Information for the user. Kalcipos-D forte 500 mg/800 IU film-coated tablets. Calcium/cholecalciferol (Vitamin D3) Package leaflet: Information for the user Kalcipos-D forte 500 mg/800 IU film-coated tablets Calcium/cholecalciferol (Vitamin D3) Read all of this leaflet carefully before you start using this medicine

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

Amidex 1 mg film-coated tablets

Amidex 1 mg film-coated tablets Package leaflet: Information for the user Amidex 1 mg film-coated tablets Anastrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence

More information

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Valaciclovir Teva 500 mg Film-coated Tablets. Valaciclovir

PACKAGE LEAFLET: INFORMATION FOR THE USER. Valaciclovir Teva 500 mg Film-coated Tablets. Valaciclovir PACKAGE LEAFLET: INFORMATION FOR THE USER Valaciclovir Teva 500 mg Film-coated Tablets Valaciclovir Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may

More information

European Medicines Agency decision

European Medicines Agency decision EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)

More information

Package leaflet: Information for the user

Package leaflet: Information for the user PACKAGE LEAFLET 1 Package leaflet: Information for the user Clopidogrel/Acetylsalicylzuur Billev 75 mg/75 mg filmomhulde tabletten Clopidogrel/Acetylsalicylzuur Billev 75 mg/100 mg filmomhulde tabletten

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

1. What Bisoprolol Fumarate tablet is and what it is used for

1. What Bisoprolol Fumarate tablet is and what it is used for Package leaflet: Information for the user Bisoprolol 2.5 mg film-coated tablets Bisoprolol 5 mg film-coated tablets Bisoprolol 10 mg film-coated tablets Bisoprolol fumarate Read all of this leaflet carefully

More information

Package Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil

Package Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil Package Leaflet: Information for the user Tadalafil 10 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

European Union herbal monograph on Symphytum officinale L., radix

European Union herbal monograph on Symphytum officinale L., radix 5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs

More information

European Medicines Agency decision

European Medicines Agency decision EMA/106209/2017 European Medicines Agency decision P/0074/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 November 2017 EMA/845743/2017 Human Medicines Evaluation Division Active substance: ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus) Procedure no.: PSUSA/00010345/201702 30 Churchill

More information

European Medicines Agency decision

European Medicines Agency decision EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/593212/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): flurbiprofen Procedure No.: PSUSA/00001450/201611 30 Churchill

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

European Medicines Agency decision

European Medicines Agency decision EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)

More information

Package leaflet: Information for the patient. Optinate 30 mg film-coated tablets risedronate sodium

Package leaflet: Information for the patient. Optinate 30 mg film-coated tablets risedronate sodium Package leaflet: Information for the patient Optinate 30 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Package leaflet: Information for the user. Ibandroninezuur STADA 150 mg, filmomhulde tabletten. Ibandronic acid

Package leaflet: Information for the user. Ibandroninezuur STADA 150 mg, filmomhulde tabletten. Ibandronic acid Package leaflet: Information for the user Ibandroninezuur STADA 150 mg, filmomhulde tabletten Ibandronic acid Read all of this leaflet carefully before you start taking this medicine because it contains

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501292/2014 European Medicines Agency decision P/0227/2014 of 5 September 2014 on the acceptance of a modification of an agreed paediatric investigation plan for aliskiren (Rasilez and associated names),

More information